Gilenya (Fingolimod): A Sphingosine 1-Phosphate Receptor Modulator

By Dr. Emily Hanover

Gilenya (Fingolimod): A Sphingosine 1-Phosphate Receptor Modulator is a comprehensive guide to one of the most groundbreaking treatments for multiple sclerosis (MS). As the first oral disease-modifying therapy approved for MS, Gilenya revolutionized the treatment landscape by offering an alternative to traditional injectable therapies. This book explores the drug's pharmacology, mechanism of action, clinical applications, safety profile, and its impact on MS management.

Written for healthcare professionals, researchers, and patients seeking a deeper understanding of Gilenya, the book delves into its role as a sphingosine 1-phosphate receptor modulator, its effects on immune cell function, and the latest clinical trial findings. It also examines Gilenya's efficacy compared to other disease-modifying therapies, potential side effects, and future directions in the field of MS treatment.

With a clear and evidence-based approach, this book serves as an essential resource for anyone interested in the science and clinical use of Gilenya.

• Format: Paperback
• Language: English
• ISBN: B0F196QR1K
• ISBN13: 9798313827858
• Release Date: March 2025
• Publisher: Independently Published
• Length: 210 Pages
• Weight: 0.63 lbs.
• Dimensions: 0.4" x 6.0" x 9.0"